Loading compound...
Cyclin-dependent kinase (CDK) inhibitor
Dinaciclib is a small molecule drug currently being studied in clinical trials. It works by inhibiting several types of cyclin-dependent kinases (CDK 1, 2, 5, and 9), which are enzymes that help regulate the cell cycle.
How it worksDinaciclib stops the growth of cancer cells by blocking specific enzymes (CDKs) that the cells need to divide and multiply.
Used for
Chronic lymphocytic leukemia (under study)Multiple myeloma (under study)Acute lymphoblastic leukemia (under study)Acute myeloid leukemia (under study)Melanoma (under study)Prolymphocytic leukemia (under study)Breast cancer (under study)
Conditions
Chronic lymphocytic leukemiaMultiple myelomaAcute lymphoblastic leukemiaAcute myeloid leukemiaMelanomaProlymphocytic leukemiaBreast cancer
Class
CDK inhibitorSmall moleculeCyclin-dependent kinase (CDK) inhibitorImmune systemHematologic system
How to take
Dinaciclib is currently in various stages of clinical research (Phase 1, 2, and 3) and is not yet widely approved for general use as described in the provided data.
Talk to your doctor
Questions to ask
- ·Is Dinaciclib part of a clinical trial I am eligible for?
- ·How does Dinaciclib target my specific type of cancer?
- ·What are the expected outcomes of Dinaciclib treatment?
Educational summary derived from FDA labeling, AI-assisted. Not medical advice — consult a healthcare professional. Updated 2026-04-26.
